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The aim of this study was to assess changes in the costs of asthma drug therapy before and during the use of chronic
montelukast treatment in the U.K. A retrospective cohort analysis of a primary care database in the U.K. was
carried out. Patients with chronic montelukast use (140 once-daily doses) were selected for analysis.
Benchmarking data were obtained for matched patients with chronic inhaled corticosteroid (ICS) use and patients
with chronic salmeterol therapy with concomitant ICS use. The main outcome measures were changes in utilization
and monthly cost of asthma therapies costs. Asthma patients experienced significant (P50?05) reductions in the
monthly costs of ICS, short-acting b-agonists and antibiotics following chronic montelukast therapy. Monthly
concomitant drug costs were reduced by £7?49 per month, which offset 27?5% of the additional cost of
montelukast, yielding an increase in total drug costs of £19?78 per month. Meanwhile, increased total drug costs for
matched patients with chronic ICS use, and matched patients with chronic salmeterol therapy and concomitant ICS
use, increased by £5?37 per month and £44?55 per month respectively. Additionally, patients using chronic
montelukast therapy experienced a statistically significant (P50?05) reduction in the use of short acting b-agonists,
and antibiotics, suggesting improvement in asthma control.
Chronic use of montelukast therapy is associated with a reduction of concomitant drug therapy costs.
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Asthma is a chronic disease of the airways that currently
aicts over 100 million people worldwide, and constitutes a
serious public health problem in countries throughout the
world (1). Because of its high prevalence and significant
morbidity, asthma represents a tremendous economic
burden to society both in the direct costs of medical
treatment, including hospitalization and doctor’s visits, as
well as indirect costs due to lost productivity. In the U.K.,
the total annual cost of asthma (indirect and direct) is
estimated to be £322 million (2). It has been estimated that
three quarters of the total cost of asthma is related to
hospitalization, emergency admission and lost productivity
at work or school resulting from poor asthma control (3).
Thus, improving control has the potential to greatly reduce
the economic burden of this disease.
Leukotriene receptor antagonists, a new class of oral
asthma controlling medications, have been recently intro-Received 9 June 2000 and accepted in revised form 25 October
2000.
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antagonist montelukast improved asthma control when
used alone or with concomitant inhaled corticosteroids
(ICS) (4–7). Use of montelukast may also facilitate
reductions in ICS dosage and b-agonist use (8,9). There-
fore, physicians who use montelukast may change their
prescribing patterns and attempt to reduce the use of such
concomitant asthma therapies.
The purpose of this study was to assess prescribing
patterns of GPs by estimating changes in the per patient
costs of asthma medications following chronic use of
montelukast therapy. To provide benchmarking informa-
tion, changes in asthma drug therapy costs for matched
patients receiving chronic inhaled corticosteroids (ICS) and
matched patients with chronic use of salmeterol, a long-
acting b-agonist, with concomitant ICS use were also
evaluated. The study was based on a retrospective analysis
of data from a cohort of asthma patients in the U.K.
Methods
Drug utilization data were obtained from the U.K.
Mediplus1 database. This database contains diagnosis
and prescribing information on more than one million
patients from a nationally representative sample of
545GPs. The database was searched from 1 February# 2001 HARCOURT PUBLISHERS LTD
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years of age) with chronic use of asthma therapy and one of
the following computer recorded diagnoses were included
in the analysis: asthma, extrinsic asthma, intrinsic asthma,
status asthmaticus, or asthma attack. Patients with
computer recorded diagnoses of chronic obstructive pul-
monary disease, chronic bronchitis, or emphysema were
excluded.
To assess changes in asthma drug utilization associated
with chronic use of montelukast therapy, data were
obtained for at least 140 days before and after each
patient’s first montelukast prescription. The date of the first
montelukast prescription was defined as the index prescrip-
tion date (IPD). Chronic montelukast therapy was defined
as at least 140 once daily doses within 6 months following
the IPD. The length of the patients’ montelukast therapy
was estimated as the number of days from the IPD to the
last montelukast prescription date plus the number of
montelukast daily doses supplied by the last prescription.
The time period of analysis before the IPD was the same as
the length of the patients’ montelukast therapy. All patients
who met the above criteria were evaluated, regardless of
concomitant asthma therapy.
To obtain benchmarking information, two additional
groups were analysed by one-to-one matching of patients in
each group to montelukast patients. To ensure that patients
can be classified into only one group the following scheme
was utilized: (i) chronic ICS use without montelukast
(patients with three or more ICS prescriptions following the
IPD of the matching montelukast patient); and (ii) patients
using chronic salmeterol treatment with concomitant ICSFIG. 1. Scheme for matching chronic montelukast patients with
salmeterol with concomitant ICS use. 1Same number (+1) presc
IPD. 2Index Prescription Date.(patients with five or more salmeterol prescriptions starting
within 30 days of the date of the matching montelukast
patient’s IPD). As salmeterol is not licensed for first line
therapy in the U.K., salmeterol patients were also required
to have at least one ICS prescription after the initiation of
salmeterol treatment. It was estimated that an ICS
prescription could last up to approximately 1?5 months,
and that a salmeterol prescription could last up to 1 month.
Thus, the cutoff points requiring three prescriptions for the
ICS cohort and five prescriptions for the salmeterol cohort
after the IPD were chosen as they were considered sucient
to indicate chronic use of therapy in the 5–6 months
following the IPD. As few salmeterol initiations are likely
to occur on the same day within the matching criteria set,
we allowed +1 month to enable sucient recruitment, but
not so broad as to allow major seasonal factors to affect the
data. For evaluation purposes, the IPD for each ICS
patient was defined to be the same as the IPD of the
matching montelukast patient; and for salmeterol patients,
the IPD was defined as the date of salmeterol initiation.
Patients were matched based on gender, age (+5 years), the
length and dates of asthma therapy, and asthma severity,
requiring matched patients to have had the same number of
prescriptions (+1) for short acting b-agonist for the 3
months before each patient’s IPD (Fig. 1).
Monthly use of the following asthma drugs was
evaluated: ICS, long-acting b-agonists, short-acting
b-agonists and antibiotics. Drug use was assigned monetary
value by means of the per pack pharmacy purchase price
for each specific brand or generic drug prescribed obtained
from contemporaneous issues of the British Pharmaceuticalpatients using chronic ICS and patients using chronic
riptions for short-acting b-agonists in 3 months before the
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Asthma control was estimated by evaluating the monthly
average number of packs prescribed or prescriptions per
patient of short-acting b-agonists, antibiotics and oral
steroids. Hypotheses were made a priori and hypothesis
testing to determine if monthly use in terms of cost and
packs prescribed were different before and after the IPD
was performed using paired t-test with a=0?05 to
determine statistical significance. Bootstrap confidence
intervals were estimated to validate the results of t-test.
(10). Results are reported as statistically significant when
both methods showed P50?05.
Results
There were 68 861 asthma patients in the database, of
whom 189 patients were found to have been initiated on
montelukast. Only 94 patients, however, met the inclusion
criteria of having already received at least 140 once daily
doses within 6 months and, of these, 89 were able to be
matched to chronic ICS patients and were included in the
study. Forty-nine of the patients having chronic salmeterol
use with concomitant ICS use met the inclusion criteria and
could be matched to chronic montelukast patients and
included in the analysis. The matched groups’ average
number of short-acting b-agonist prescriptions during the 3
months prior to the IPD did not differ among groups
(Table 1).
Patients in both montelukast groups received higher
levels of concomitant asthma drug therapy than their
respectively matched patients in the ICS and salmeterol
groups (Tables 2 and 3). Of the 89 montelukast patients
matched with ICS 44?9% and 87?6% used concomitant
salmeterol or ICS, respectively, after the IPD. Of the 49
montelukast patients matched with salmeterol 49?4% and
85?7% used concomitant salmeterol or ICS, respectively,
after the IPD.TABLE 1. Summary of patient demographics for each study grou
Montelukast vs. chronic
Montelukast IC
N 89 8
Age (mean+SD) 54?2+16?6 54?2+
% Female 60?7% 60?
Average number of SAbA*
Prescriptions 3 months 1?9 1
Before IPD{
Days of study period
After IPD{ Mean 192?0 19
Range (140–247) (140–
*Short-acting b-agonist.
{Index Prescription Date.
{Days of study period before IPD=Days of study period afterPatients in the montelukast cohort experienced signifi-
cant reductions (P50?05) in the monthly costs of ICS,
short-acting b-agonists and antibiotics following chronic
use of montelukast therapy. The total reduction of non-
montelukast drug costs was £7?49 per month. This cost
reduction offset the £27?27 per month additional cost of
monetelukast by 27?5%, resulting in net additional drug
costs associated with montelukast use of £19?78 per month.
In addition, chronic montelukast patients experienced
significant reductions (P50?05) in the number of packs of
short-acting b-agonists and antibiotics prescribed, and a
non-significant reduction (P40?05) in packs of oral
steroids prescribed (Table 2).
Matched patients using chronic ICS treatment experi-
enced significant (P50?05) increases in the monthly costs of
ICS over the same time period as their matched chronic
montelukast patients. The total drug costs for matched
chronic ICS patients increased by £5?37 per month over
costs before the IPD. In addition, matched chronic ICS
patients experienced a significant increase (P50?05) in the
number of packs of short-acting b-agonists, but non-
significant reductions (P40?05) in the number of packs
of antibiotics and oral steroids prescribed after the IPD
(Table 2).
Patients with chronic salmeterol use and concomitant
ICS use experienced a significant increase (P50?05) in the
monthly costs of ICS following initiation of salmeterol.
Including the cost of salmeterol, the total drug costs for
these patients increased by £44?55 per month over costs
before the IPD. Meanwhile, patients with chronic mon-
telukast use matched to these salmeterol patients experi-
enced significant reductions (P50?05) in the monthly costs
of short-acting b-agonists and antibiotics following initia-
tion of therapy. Including the cost of montelukast, the total
drug costs for the matched chronic montelukast patients
increased by £22?76 per month. Chronic salmeterol patients
with concomitant ICS use experienced a non-significant
reduction (50?5%) (P40?05) in the number of short-p
ICS Montelukast vs. chronic salmeterol with ICS
S Montelukast Salmeterol
9 49 49
17?0 54?6+14?1 54?8+14?4
7% 63?3% 63?3%
?8 1?6 1?5
2?0 192?8 192?8
247) (140–238) (140–238)
IPD.
TABLE 2. Asthma therapy cost and utilization changes among patients using chronic montelukast therapy and patients with
chronic ICS use before and after IPD
Montelukast ICS
Before IPD{
n=89
After IPD{
n=89
Change{ Before IPD{
n=89
After IPD{
n=89
Change{
Monthly cost (£)
mean+SD
ICS 20?28+23?71 15?43+17?66 74?85*+18?72 9?72+10?55 14?25+13?05 4?52*+9?68
Long-acting b-agonist 9?83+13?74 9?64+13?74 70?19+10?81 3?97+8?76 4?70+10?30 0?73+5?22
Short-acting b-agonist 4?93+9?02 3?27+5?93 71?66*+5?05 1?71+2?77 1?95+2?61 0?24+1?22
Antibiotics 1?88+3?30 1?09+1?92 70?79*+3?14 0?62+1?31 0?50+1?50 70?12+1?36
Total non-montelukast 36?92+35?78 29?43+25?64 77?49*+24?63 16?02+18?22 21?40+19?77 5?37*+13?14
Montelukast 0 27?27+4?47 27?27+4?47 0 0 0
Total monthly drug costs 36?92+35?78 56?70+26?16 19?78+24?85 16?02+18?22 21?40+19?77 5?37*+13?14
Packs prescribed}
Short-acting b-agonists 1?06+1?27 0?86+1?11 719%* 0?56+0?71 0?66+0?66 18%*
Antibiotics 0?18+0?25 0?12+0?16 733%* 0?06+0?12 0?06+0?16 72%
Oral steroids 0?10+0?16 0?07+0?16 730% 0?03+0?12 0?02+0?11 733%
*Change is statistically significant (P50?05).
{Index Prescription Date.
{Change from before index prescription date to after index prescription date.
}Change in number of packs prescribed (after index prescription date minus before index prescription date), expressed as a
percentage of packs prescribed before index prescription date.
TABLE 3. Asthma therapy cost and utilization changes among patients using chronic montelukast therapy and patients with
chronic salmeterol and concomitant ICS use before and after IPD
Montelukast ICS
Before IPD{
n=49
After IPD{
n=49
Change{ Before IPD{
n=49
After IPD{
n=49
Change{
Monthly cost (£)
mean+SD
ICS 19?96+24?96 17?56+20?53 2?40+17?54 11?94+17?99 25?24+20?08 13?30*+20?25
Long-acting b-agonist 10?50+15?31 10?90+16?23 0?40+12?46 0?48+3?39 30?93+9?51 30?45+10?03
Short-acting b-agonist 4?66+9?68 2?93+5?62 71?73*+5?74 2?71+7?94 2?97+7?64 0?26+2?86
Antibiotics 2?19+3?73 1?04+1?55 71?15*+3?89 1?44+5?69 1?98+8?10 0?54+7?53
Total non-montelukast 37?31+37?94 32?43+28?79 74?88+25?78 16?57+30?65 61?12+31?44 44?55*+3?95
Montelukast 0 27?64+4?87 27?64+4?87 0 0 0
Total monthly drug costs 37?31+37?94 60?07+29?51 22?76*+26?09 16?57+30?65 61?12+31?44 44*?55+3?95
Packs prescribed}
Short-acting b-agonists 0?88+1?03 0?70+0?93 720% 0?81+1?69 0?81+1?32 750?5%
Antibiotics 0?21+0?28 0?12+0?18 743%* 0?15+0?15 0?35+1?83 133%
Oral steroids 0?8+0?12 0?06+0?16 725% 0?05+0?09 0?05+0?14 2%
*Change is statistically significant (P50?05).
{Index Prescription Date.
{Change from before index prescription date to after index prescription date.
}Change in number of packs prescribed (after index prescription date minus before index prescription date), expressed as a
percentage of packs prescribed before index prescription date.
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significant (P40?05) increases in the number of prescrip-
tions for antibiotics and oral steroids after the IPD. In
contrast, matched chronic montelukast patients experi-
enced a significant reduction (P50?05) in the number of
packs of antibiotics prescribed, and non-significant reduc-
tions (P40?05) in the number of packs of short-acting
b-agonists and oral steroids prescribed (Table 3).
Discussion
Primary care physicians in the U.K. have restricted
prescribing budgets. This may limit their willingness to
use new therapies which appear to be superficially
expensive. This study provides prescribing cost data that
is necessary for those making decisions about prescribing
costs including cost-conscious physicians. This real world
data about prescribing patterns associated with chronic use
of montelukast during its first year of use supplies such
information. Consequently, sample sizes are small with
only 189 patients commenced on montelukast within the
first year due to initial low prescribing.
The results indicate that chronic use of montelukast is
associated with a significant reduction in the costs of
concomitant asthma drug therapy. Patients using chronic
montelukast therapy were found to have statistically
significant reductions in the monthly costs of ICS, short-
acting b-agonists and antibiotics following initiation of
therapy. The reductions in concomitant drug costs provided
a partial offset of the cost of montelukast for these patients.
It is important to benchmark such data as far as possible
by using comparator patients matched as far as possible to
take account of any confounding factors. One confounding
factor that is dicult to remove is the different knowledge
and skills of the prescribing physician. The study provides
benchmarking information about matched patients receiv-
ing chronic ICS therapy and matched patients receiving
chronic salmeterol therapy with concomitant ICS. Patients
were matched to patients on montelukast for severity based
upon use of short-acting b-agonists before the IPD. The
results show an increase in the costs of drug therapy in all
the study groups. This suggests that physicians prescribed
montelukast to patients they considered in need of
additional therapy and that the matching algorithm
identified patients who probably needed additional therapy
in the two benchmarking groups. Indeed, the results show
that physicians increase their prescribing of asthma
medications to patients in the two benchmarking groups.
This was a retrospective study and thus limited by the
characteristics of the database. All hypotheses were made a
priori, however, and participant and selection biases that
can occur in prospective clinical studies did not exist. The
results of this study were limited to those patients with
chronic use of montelukast and therefore cannot be
extrapolated to patients with intermittent use or those
who initiate but discontinue therapy. Because the database
contained only information on prescriptions, the study was
limited to calculating drug costs, with no measure of other
direct and indirect costs associated with asthma. Moreover,since no measure of effectiveness was available, cost-
effectiveness determinations were impossible to make.
While attempts to match demographics, seasonal effects
and asthma severity among patient groups were as diligent
as possible, there may have been differences between
patients that the database was not able to portray, such
as differences between the characteristics of patients
receiving each treatment. Indeed, assessment of prescribing
patterns before the IPD shows higher consumption of
asthma drug therapies by patients in the two montelukast
groups than their respectively matched patients.
Changes in prescribing patterns are particularly interest-
ing for the 49 patients who were matched to the patients
initiated on salmeterol. Both patients groups required an
initiation of additional asthma therapy, salmeterol or
montelukast, and were matched for severity on levels of
short-acting b-agonists prescriptions before IPD. However,
cost of asthma drug therapy before IPD was much higher
among patients who received montelukast than among
patients who received salmeterol resulting in similar
monthly costs at the end of the study for both groups
(60?07 and 61?12). This shows that during the first year of
montelukast usage in the U.K., when prescribing montelu-
kast, the physicians reduced their prescribing of concomi-
tant asthma therapies. When prescribing salmeterol the
physicians increased their prescribing of concomitant
asthma therapies. This may suggest that patients on high
levels of asthma therapy who started montelukast could
achieve an improvement in asthma control as measured by
reductions in the use of short-acting b-agonists, antibiotics
and oral steroids at a comparable cost of prescribing
salmeterol.
There may also have been differences in the prescribing
patterns of physicians. Physicians who prescribed monte-
lukast may have been aware of the published clinical studies
suggesting that montelukast may enable ICS tapering.
While this would explain the reduction in the cost of ICS, it
cannot account for the reductions in packs of short-acting
b-agonists and antibiotics prescribed.
The concomitant drug cost reductions of £7?49 per
month for chronic montelukast patients do not appear to
be the result of seasonal differences. Matched patients on
chronic ICS over the same time period experienced an
increase in total asthma drug costs of £5?37 per month.
Assuming the montelukast and matched patient groups are
comparable, combining the £7?49 per month cost reduc-
tions associated with use of chronic montelukast therapy
with the £5?37 per month cost increase associated with
chronic ICS therapy would yield a total expected savings of
£12?86 per month in non-montelukast drug costs for
chronic montelukast therapy, as compared with chronic
ICS therapy in patients with asthma that in retrospect
merited an increase in asthma therapy. This amount would
offset 47?2% of the monthly cost of montelukast, resulting
in a net additional cost for chronic montelukast use of
£14?41 per month.
Clinical studies have reported that the effectiveness
of chronic salmeterol therapy may be partially limited
by tolerance that has been observed within 4 weeks
of continued use (11,12). Patient tolerance to chronic
88 D. B. PRICE ET AL.montelukast therapy has not been observed in clinical
studies with durations of up to 2?4 years (4–6,9,13). Patients
with chronic use of salmeterol therapy did not appear to
experience improvement in asthma control over the 6
month duration of this study, as measured by the
consumption of short-acting b-agonists, antibiotics and
oral steroids. Moreover, while similar monthly costs were
observed for both groups at the end of the study, the total
increase in monthly drug therapy costs for chronic
salmeterol patients was £21?79 pounds per month more
than that for matched chronic montelukast patients.
The study evaluates changes in prescribing patterns and
is not intended to provide information about the relative
effectiveness of the different therapeutic approaches eval-
uated. While there were no measures of effectiveness, the
study chose, as a surrogate of asthma control, to assess the
change in the average number of packs prescribed for three
medications: oral steroids, often prescribed as emergency
treatment in hospitals; antibiotics, often prescribed to treat
infections; and short-acting b-agonists, commonly used for
relief of asthma exacerbations. Patients dispensed more
than eight b-agonist prescriptions per year have been found
to have a hospitalization risk four times that of patients
dispensed no b-agonists (14). Patients on chronic montelu-
kast therapy experienced reductions in the average number
of packs of all three medications prescribed, with the
reduction being statistically significant for both short-acting
b-agonists and antibiotics. These results suggest that use of
chronic montelukast therapy improves control of patients’
asthma. The results are consistent with previous clinical
studies of montelukast. Compared to placebo therapy,
montelukast treatment was less likely to be associated with
b-agonist rescue therapy (5). Additionally, studies have
demonstrated that montelukast use allows the tapering
of ICS dosage while maintaining or increasing asthma
control (8).
Improving asthma control may require additional
therapy and, therefore, increased drug costs, however, it
is likely that cost reductions in other areas, including
hospitalization and lost productivity, may more than
offset these increases (15,16). A review of nine cost-of-
illness studies throughout the world has indicated that drug
costs represent approximately 37% of the direct costs of
asthma (3). Previous cost-effectiveness studies of ICS have
demonstrated that improvement of asthma control can
markedly reduce non-drug costs (17,18). Since the results
suggest that chronic montelukast use may improve asthma
control, there may be additional direct cost savings
associated with chronic montelukast treatment that are
not reflected in this study. These potential additional
savings may further offset the cost of montelukast or result
in net savings.
Whilst registration trials reveal effectiveness of new
pharmaceuticals in tightly controlled circumstances and
patients who meet study entry criteria it is important to
look at their impact on costs and effectiveness in clinical
practice. Use of large primary care databases is one method
of providing such data (19) in advance of data from
pragmatic or ‘real-world’ clinical trials—although database
information only reveals limited information about effec-tiveness as measured by relief and emergency drug
treatment.
CONCLUSION
This study demonstrated that chronic montelukast therapy
resulted in a reduction in the costs of concomitant asthma
drug therapy, which offset a portion of the monthly cost of
montelukast. This study was limited to evaluating only the
cost of drug therapy; however, montelukast may potentially
reduce other costs associated with asthma, both direct and
indirect. Further studies elucidating the cost-effectiveness of
montelukast are warranted.
Key Messages
(i) Asthma patients with use of chronic montelukast
therapy may experience a reduction in the cost of
concomitant asthma drugs, which offsets all or a
portion of the monthly cost of montelukast.
(ii) Chronic montelukast patients may demonstrate an
improvement in asthma control as measured by
reductions in the use of short-acting b-agonists,
antibiotics and oral steroids.
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